Search

Your search keyword '"Bruin‐Weller, M.S."' showing total 2 results
Start Over Author "Bruin‐Weller, M.S." Topic allergies Publication Year Range Last 10 years
2 results on '"Bruin‐Weller, M.S."'

1. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts.

Author

Ring, J., Worm, M., Wollenberg, A., Thyssen, J.P., Jakob, T., Klimek, L., Bangert, C., Barbarot, S., Bieber, T., Bruin‐Weller, M.S., Chernyshov, P.V., Christen‐Zaech, S., Cork, M., Darsow, U., Flohr, C., Fölster‐Holst, R., Gelmetti, C., Gieler, U., Gutermuth, J., and Heratizadeh, A.

Subjects
COVID-19 vaccines, SKIN diseases, ALLERGIES, MEDICAL personnel, ECZEMA, PHYSICIANS
Abstract

Dr. Seneschal has been an investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non-financial support from LEO Pharma, Pierre Fabre, Sanofi-Genzyme and Bioderma. Dr. Vestergaard has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. [Extracted from the article]

Published
2021
Full Text
View/download PDF

2. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis.

Author

Schaft, J., Politiek, K., Reek, J.M.P.A., Christoffers, W.A., Kievit, W., Jong, E.M.G.J., Bruijnzeel‐Koomen, C.A.F.M., Schuttelaar, M.L.A., and Bruin‐Weller, M.S.

Subjects
IMMUNOSUPPRESSIVE agents, IMMUNOPHARMACOLOGY, ATOPIC dermatitis treatment, ALLERGIES, SKIN inflammation
Abstract

Background Long-term data of ciclosporin A (CsA) treatment in daily practice in patients with severe atopic dermatitis ( AD) are lacking. Objectives To perform a detailed analysis of drug survival, which is the length of time a patient continues to take a drug, for CsA in a long-term daily practice cohort of patients with AD. The secondary objective was to identify determinants of drug survival. Methods Data were extracted from a retrospective cohort of patients treated with CsA for AD. Drug survival was analysed using Kaplan-Meier survival curves. Determinants of drug survival were analysed using uni- and multivariate Cox regression analyses with backward selection. Results In total, 356 adult patients were analysed (386 patient-years). The overall drug survival rates were 34%, 18%, 12% and 4% after 1, 2, 3 and 6 years, respectively. Reasons for discontinuation were controlled AD (26·4%), side-effects (22·2%), ineffectiveness (16·3%), side-effects plus ineffectiveness (6·2%) or other reasons (11·0%). Older age was associated with a decreased drug survival related to controlled AD [hazard ratio ( HR) 0·91]. Older age was also associated with a decreased drug survival related to side-effects ( HR 1·14). An intermediate-to-high starting dose (> 3·5-5·0 mg kg−1 daily) was associated with an increased drug survival related to ineffectiveness ( HR 0·63). Conclusions This is the first study on drug survival for CsA treatment in AD. Older age was associated with decreased drug survival related to controlled AD and side-effects. An intermediate-to-high starting dose was associated with an increased drug survival related to ineffectiveness. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results